CPhA PRE-BUDGET CONSULTATION BRIEF Prescriptions for a healthy and productive Canada

Similar documents
Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO

Drugs for Rare Disorders

2018/ /21 SERVICE PLAN

Minister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018

MINISTRY REPONSE TO THE ONTARIO CITIZENS COUNCIL REPORT: INFORMING THE DEVELOPMENT OF A NEW DRUG PROGRAM IN ONTARIO

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.

Responding to BC s Opioid Overdose Epidemic

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

POLICY AND ECONOMIC CONSIDERATIONS FOR FRAILTY SCREENING IN THE CANADIAN HEALTHCARE SYSTEM

CANNABIS IN ONTARIO S COMMUNITIES

A1. Does your government have a formal, written diabetes policy or strategy?

Health Care Reform: Implications for Public Health. Susan Polan, PhD. American University Next steps in Health Reform 2017

CHARTING THE COURSE FOR CANADA S NATIONAL DEMENTIA STRATEGY PRE-BUDGET SUBMISSION TO THE HOUSE OF COMMONS STANDING COMMITTEE ON FINANCE

Oral Health: A call to action

HL3.01 REPORT FOR ACTION. Toronto Indigenous Overdose Strategy SUMMARY

December 18, Submitted Electronically

Harm Reduction Program Enhancement Questions and Answers. Population and Public Health Division Ministry of Health and Long-Term Care

Office of the Auditor General Portage Avenue Winnipeg, Manitoba R3C 0C4

HEALTHY CANADIANS AND SUSTAINED ECONOMIC RECOVERY: PREDICTABLE VACCINE FUNDING IN CANADA

Presentation to the Standing Committee on Health Chronic Diseases Related to Aging. October 17, 2011

Alberta Health Office of the Chief Medical Officer of Health. Responding to Alberta s opioid crisis Public progress report: 2

Review of Controlled Drugs and Substances Act

Oral Health in Canada: a Federal Perspective. Canadian Agency of Drugs and Technology in Health (CADTH)

RE: CONSULTATION ON DRAFT - DRUG AND NATURAL HEALTH PRODUCTS RECALL GUIDE

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

HL18.3 REPORT FOR ACTION. Toronto Overdose Action Plan: Prevention & Response SUMMARY

REPORT CARD A STRATEGIC FRAMEWORK TO END VIOLENCE AGAINST ABORIGINAL WOMEN A PARTNERSHIP OF:

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

Higher rate now: Why excise tax on tobacco is long overdue for an increase

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW

PHARMACISTS IN NEWFOUNDLAND AND LABRADOR

Canadian Mental Health Association

The Burden of Kidney Disease in Rural & Northern Ontario

Canadian Health Care Systems

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:

Opioids - Fentanyl - Naloxone. Public Health Nurse

The Challenge of Treating Pain

NALOXONE RISK ASSESSMENT

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.

UHC. Moving toward. Ghana NATIONAL INITIATIVES, KEY CHALLENGES, AND THE ROLE OF COLLABORATIVE ACTIVITIES. Public Disclosure Authorized

Prescription for Progress Study conducted by the Siena College Research Institute April 10 - May 4, Stakeholders - MOE +/- 4.

Next Steps and Transitioning the Task Force Mayor s Task Force on Mental Health & Addictions Council Presentation 21 FEBRUARY 2017

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Addressing Gaps in MS Care. November 6, :00 AM - Noon

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

2019 Board of Directors Elections Candidate Statement SANDY RENNIE

Medicaid s Role in Combating the Opioid Crisis

Opioids Are Seniors at Risk? (April 26, 2018)

OPIOID EMERGENCY RESPONSE REGULATION

Canadian Mental Health Association

CITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA

Decriminalization of Personal Use of Psychoactive Substances

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Public Health Association of British Columbia

Notes for Remarks Dr. Jan Hux, President and Kimberley Hanson, Director, Federal Affairs Diabetes Canada. To the Standing Committee on Health

Decriminalization of Personal Use of Psychoactive Substances

GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE

An Investment in Public Health: An Investment in Canada s Future Prosperity

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

REAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE

Needle and Syringe Programs - 17 October 2013

SASKATCHEWAN S HIV STRATEGY UPDATE

Responding to BC s Overdose Epidemic

INTERNAL QUESTIONS AND ANSWERS DRAFT

Speaking Notes. - TB in First Nations and Inuit Communities -

March XX, Washington, DC Washington, DC Washington, DC Washington, DC 20515

Renewable World Global Gender Equality Policy

Financial Disclosure. Diabetes in the State of Florida. The Scope of Diabetes in Florida(cont.) The Scope of Diabetes in Florida

Advancing the National HIV/AIDS Strategy: Housing and the HCCI. Housing Summit Los Angeles, CA

Economic and Social Council

Children and AIDS Fourth Stocktaking Report 2009

Kay Johnson, MPH, EdM February 14, 2012 Association of Maternal and Child Health Programs, Washington DC

PHARMACISTS IN CANADA

Alex Azar Secretary, Department of Health and Human Services

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

STATE AND COMMUNITY MODELS FOR IMPROVING ACCESS TO DENTAL CARE FOR THE UNDERSERVED

Sustain and Seize Cancer Research Opportunities

Strategies for Federal Agencies

Changes to Publicly-Funded Physiotherapy Services

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

Background. Recommendation 1

1.2 Building on the global momentum

Eliminating Viral Hepatitis in Australia: Where are we in 2017?

Time to Think (and Act) Differently:


Linking Public Interests to Ensure Sustainable Statewide Quitlines

ENDING HEALTH DISPARITIES: A Congressional Black Caucus Priority

Re: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments

Countdown to 2015: tracking progress, fostering accountability

Submission to Standing Committee on Health. With no leadership, Canada s diabetes crisis will continue to get worse

No one should be at risk of poor health because of their social and economic situations.

January 16, Dear Administrator Verma:

I. Include Community Mental Health and Addiction Services Providers in Federal HIT Funding Opportunities

CANADIAN DIABETES ASSOCIATION

The Dental Therapist Project: Expanding Care to Every Community

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

Transcription:

CPhA PRE-BUDGET CONSULTATION BRIEF 2018 Prescriptions for a healthy and productive Canada

Introduction On behalf of the Canadian Pharmacists Association (CPhA) and Canada s 40,000 pharmacists, we are pleased to provide the Committee with our recommendations for Budget 2018. Although pharmacists practice in many different settings, including hospitals and family health teams, pharmacists are mostly known as accessible community health care providers. They are located in almost every community and, on average, they interact with their patients 14 times per year. They are available late at night and on weekends and are there to serve Canadians from all walks of life. As drug experts, pharmacists have a unique role to play in our health care system, in ensuring appropriate use of medication and in promoting patient safety. They are also increasingly playing a critical role in providing primary health care services to patients, such as chronic disease management, administering flu shots and smoking cessation, to name a few. 2 Prescriptions for a healthy and productive Canada

As the Committee well knows, health and productivity are intrinsically linked. People who are in poor health are less likely to be able to contribute to the economic growth and success of Canada. Equally important to productivity is ensuring timely and accessible care to Canadians so that they can go back to their work and daily lives as quickly as possible. This is why maximizing pharmacists scopes of practice across the country must be an essential strategy for all governments to improve the health and wellbeing of Canadians and increase productivity, as well as improve the efficiency of the health care system. As frontline community health care providers, we hear regularly from patients about the issues that matter to them. Our recommendations for Budget 2018, therefore, focus on four specific areas: Federal investment to equalize naloxone access across the country Federal funding to harmonize catastrophic drug coverage in Canada Investment in health science and practice-based research Equitable access to health services for indigenous drug plan beneficiaries More information is available at www.pharmacists.ca 3

Recommendations: Federal investment to equalize naloxone access across the country The Government of Canada has taken some important first steps in responding to Canada s growing opioid crisis. From preventing initial misuse of opioids to implementing evidence-based harm reduction strategies, pharmacists are key partners in reducing and addressing the negative health impacts of opioid misuse. Preventing overdose is an important piece of this complex puzzle. This is why CPhA is urging the federal government to provide provinces with targeted funding to equalize naloxone access across the country. Naloxone is a drug that can temporarily reverse an opioid overdose. When someone overdoses on opioids, their breathing either slows or stops completely. If used right away, naloxone can help them breathe normally and regain consciousness. Naloxone can either be injected or given as a nasal spray. A recent scan of naloxone availability in each province indicates that access to this life saving medication is still uneven across the country, even in communities that have been hardest hit by the opioid crisis. 1 We believe that naloxone should be made available free of charge, as widely as possible, to ensure that anyone who is at risk of an overdose has access to the medication, either themselves, through a family member or friend. Ensuring that it is available through pharmacy at no cost can help destigmatize access while ensuring that any Canadian, whether they are parents or friends, can have naloxone on hand when it is most needed. Recommendation: CPhA recommends that Budget 2018 include an investment of $15 million per year over five years so that all provinces and territories can ensure that naloxone is freely available to any Canadian who wishes to obtain a take-home kit. 1. Canadian Pharmacists Association. Environmental Scan: Access to Naloxone across Canada. July 2017. Available at: http:// www.pharmacists.ca/advocacy/opioid-crisis/ 4 Prescriptions for a healthy and productive Canada

Federal funding to harmonize catastrophic drug coverage in Canada Catastrophic drug insurance protects individuals from financial hardship due to medication expenses by imposing a maximum on out-of-pocket spending for prescription drugs. Most commonly, these plans employ a geared-to-income limit where beneficiaries pay for their drug costs until they reach a predetermined maximum calculated on the basis of their income. After this maximum is reached, the public plan pays for the remainder of drug expenses until the coverage year resets. Most Canadian provinces already provide some form of catastrophic coverage, although there is considerable variation in terms of eligibility criteria and the amount of out-ofpocket expenditures associated with each plan. We believe there is an important opportunity for the federal government to help support provincial and territorial government efforts to increase drug access for Canadians through the creation of a federal catastrophic drug transfer, with the requirement that provinces limit annual drug costs to three per cent of household income. This is lower than any of the existing provincial catastrophic plans, and would create a common standard across all provinces. 2 A catastrophic drug transfer would allow provincial drug programs to expand and improve coverage for their residents, offset the cost of provincial and territorial drug plans, and reduce disparities in coverage across the country. It would also help improve access and alleviate cost burdens for the 1 million Canadians who spend more than three per cent of after tax income on drug costs. Recommendation: CPhA calls on the federal government to create a federal catastrophic drug transfer in partnership with the provinces and territories to harmonize catastrophic drug coverage in Canada. This targeted health transfer would require additional yearly funding of approximately $1 billion a year for all provinces and territories. 2. Blomqvist, Å and Busby, Colin. Feasible Pharmacare in the Federation: A Proposal to Break the Gridlock. October 2015. Available at: https://www.cdhowe.org/sites/default/files/attachments/research_papers/mixed/e-brief_217_0.pdf. More information is available at www.pharmacists.ca 5

Investment in health science and practice-based research Research is fundamental to informing evidence-based policy decisions and shaping all aspects of our daily lives, including health care, environment and economic growth. Canada s Fundamental Science Review, released in April 2017, provides a salient observation of our current research environment and Dr. David Naylor cautions that, within the current structure, Canada s ability to innovate through research is at risk. 3 CPhA firmly supports Naylor s call to strengthen Canadian science and research by reforming the current funding, governance and coordination systems, and increasing investments to strengthen frontline research and finance early career researchers. This investment would enhance pharmaceutical sciences research, which leads to important discoveries of new therapies for preventing and treating disease and explores new models of ensuring access to the most appropriate care for Canadians. Currently, Canada s national research funding body has funded only approximately 10 per cent of grants submitted in the past several years. In addition to improvements in basic science research, CPhA believes parallel measures must be taken to bolster health and practice-based research. Thanks in large part to the Government of Canada s 2003 Primary Health Care Transition Fund, pharmacists now practice in advanced roles, providing accessible, collaborative and cost-effective primary health care to patients across Canada. Pharmacy practice research has been essential in measuring the impact of these changes and has contributed to the recognition and funding for pharmacists care in diabetes, hypertension, as well as the expansion of immunization programs to include pharmacists in most of Canada. As health care and patient needs evolve, practice-based research must continue to receive support in order to ensure that pharmacists and other providers are improving the health of Canadians, and doing so sustainably, now and in the future. Recommendation: CPhA calls on the federal government to increase research funding for fundamental basic science research as outlined in the Naylor report, as well as allocate a further $200 million over 5 years towards practice-based health research, including pharmacy practice-based research. 3. Naylor CD, Birgeneau RJ, Crago M, et al. Canada s Fundamental Science Review. April 2017. Available at: http://www. sciencereview.ca/eic/site/059.nsf/eng/home 6 Prescriptions for a healthy and productive Canada

Equitable access to health services for Indigenous drug plan beneficiaries Indigenous peoples represent the fastest-growing segment of the Canadian population and are an important part of Canada s economic prosperity. This growing population faces unique health challenges rooted in complex historical, political, legal, cultural, geographical, and jurisdictional factors. The federal government has committed to renew its relationship with Indigenous peoples and prioritize First Nations, Métis, and Inuit health care. CPhA believes that pharmacists have an important role to play in improving Indigenous health outcomes by providing quality services and medically necessary medications and benefits. The Non-Insured Health Benefits Program (NIHB) provides limited coverage for certain prescription drugs relative to other benefit plans, and does not generally cover pharmacy services. Pharmacy services are critical components of pharmacist care that improve patient health outcomes and yield drug plan savings through appropriate use and enhanced adherence. For example, the NIHB does not recognize pharmacists as prescribers for minor ailments, an important service offered in many provinces which can improve access to health care providers for patients in rural and remote areas. Nor do NIHB patients have access to publicly-funded medication assessments that help patients get the most from their medications or counselling services such as chronic disease management, including diabetes support management and smoking cessation. All patients, including First Nations, Métis, and Inuit, should have access to publicly-funded services provided by pharmacists. Recommendation: CPhA calls on the federal government to provide equitable access to health care for Indigenous peoples through increased funding for the Non-Insured Health Benefits Program (NIHB), including equitable access to publicly-funded services provided by pharmacists. More information is available at www.pharmacists.ca 7

About CPhA The Canadian Pharmacists Association (CPhA) is the uniting national voice of pharmacy and the pharmacist profession in Canada. As pharmacists undertake an enhanced role in the delivery of health care services, CPhA ensures that the profession is recognized as a national leader in health care, influencing the policies, programs, budgets and initiatives affecting the profession and the health of Canadians. More information is available at www.pharmacists.ca. For more information, contact: Joelle Walker, Director Public Affairs Canadian Pharmacists Association 1785 Alta Vista Drive, Ottawa, ON K1G 3Y6 613-523-7877 ext 387 613-523-0445 jwalker@pharmacists.ca